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Osteosarcoma is a type of bone tumour characterized by considerable levels of phenotypic
heterogeneity, aneuploidy, and a high mutational rate. The life expectancy of osteosarcoma
patients has not changed during the last three decades and thus much remains to be learned
about the disease biology. Here, we employ a RGB-based single-cell tracking system to study
the clonal dynamics occurring in a de novo-induced murine osteosarcoma model. We show
that osteosarcoma cells present initial polyclonal dynamics, followed by clonal dominance
associated with adaptation to the microenvironment. Interestingly, the dominant clones are
composed of subclones with a similar tumour generation potential when they are re-
implanted in mice. Moreover, individual spontaneous metastases are clonal or oligoclonal, but
they have a different cellular origin than the dominant clones present in primary tumours. In
summary, we present evidence that osteosarcomagenesis can follow a neutral evolution
model, in which different cancer clones coexist and propagate simultaneously.
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Osteosarcoma (OS) is the most common malignant solidtumour that affects bones. The disease presents a bimodaldistribution with increased incidence during the second
decade of life; OS represents more than 10% of solid cancer cases
in adolescents (15–19 years old)1. The paediatric incidence win-
dow reflects the biology of the disease; there is a correlation
between skeletal growth, height, and disease appearance. More-
over, OS usually originates in the extremities of long bones, close
to the metaphyseal plate, which is also the anatomical location of
bone growth2. Almost 75% of OS is highly malignant, and due to
disease aggressiveness, it has typically extended beyond the bone
into nearby musculoskeletal structures at detection1,2. Tumour
biopsies showing mesenchymal cells producing osteoid and/or
irregular woven bone are categorized as OS. The histologic
finding of this incomplete osteogenic process is a requirement for
tumour diagnosis even if other cell subtypes directly derived from
the tumour are present. This pathological definition is used
because the aetiology of OS is mostly unknown. Genetic dis-
orders, such as Li–Fraumeni syndrome (TP53 germline mutation)
and familial Retinoblastoma (RB1 germline mutation), are risk
factors for osteosarcoma3,4. The Pediatric Cancer Genome Project
(PCGP) identified frequent germline mutations of the TP53 gene
in OS, similar to the 50% TP53 mutation rate of childhood
cancers5,6, and whole genome and whole exome sequencing
revealed that alterations in the p53 and Rb pathways are more
frequent in OS than previously thought7,8. Therefore, these syn-
dromes are mainly associated with mutations of genes that par-
ticipate in genome integrity maintenance and chromosomal
stability. Unlike many sarcomas, which are characterized by
specific chromosome translocations, OS exhibits a complex kar-
yotype with high genomic and chromosomal instability;9 it is also
characterized by multiple rearrangements across the genome,
kataegis, and chromothripsis8,10–12.
Malignant tumours typically comprise a heterogeneous pool of
cells that differ in terms of morphology, phenotype, gene
expression, metabolism, immunogenicity, proliferation, and
metastatic potential13,14. Many models have been postulated to
explain the clonal dynamics that drive cancer disease and the
generation of heterogeneity14,15. The competitive linear model of
clonal cancer evolution proposed by Nowell16 and the cancer
stem cell hypothesis were the first models describing cancer
evolution17–19. Later, other authors suggested that these two
models were not mutually exclusive because cancer stem cells
could be the unit of selection during cancer initiation and pro-
gression. A switch from differentiation to self-renewal, supported
by the niche, can generate compartment amplification, in which
cancer stem cell units can also undergo independent
evolution13,20,21. With the advent of cancer genome studies,
branched phylogenies were adopted to describe cancer evolu-
tion22–25. Additionally, the sequential accumulation of genetic
alterations was recently questioned due to evidence indicating
macroevolutionary events14,26. Other authors have rejected clonal
dominance in favour of a big bang model of clonal diversity, in
which different clonal cancer populations are generated early in
tumourigenesis and coexist with neutral evolution dynamics27,28.
In this context, the ecological interaction between tumour sub-
clones29–31 and the dynamics of contingency, convergence, and
parallel evolution are implicated in tumour growth14. In the
current view of the cancer ecosystem, non-genetic determinants
also contribute to tumour growth. The interaction between
tumour cells and the microenvironment, differentiation pro-
grams, factors such as hypoxia, and especially the immune system
represent crucial players in cancer development14,21. Another
largely unexplored field of clonal cancer dynamics concerns
metastatic development. From the seed and soil hypothesis and
the preferential diffusion pathway of some tumours, the modern
definition of a pre-metastatic niche highlights the importance of
the microenvironment in metastatic cell tropism to seed-specific
organs32. Some studies have shown a monoclonal pattern of
metastatic seeding, but others have reported a polyclonal sig-
nature for this process33.
A model that exhaustively describes cancer growth is extremely
important because this knowledge has many practical implica-
tions in the clinic. Especially in the field of personalized medicine,
the clonal homogeneity of a primary tumour and heterogeneity of
metastatic cells represent relevant variables for designing a ther-
apeutic strategy. A single tumour biopsy may be insufficient to
provide representative information of the total genetic and
molecular variability present in the primary tumour. Addition-
ally, the implication of heterogeneity in the management of
patients presenting with metastatic disease represents a significant
challenge. The general approach, driven by the assumption of
close similarity between a primary tumour and metastases, has
been to analyse the primary tumour and avoid more invasive
biopsies at metastatic locations. This approach restricted the
estimation of how many different clones can constitute a tumour
or metastasize to an organ. Moreover, metastatic disease is a time-
dependent process; nevertheless, little is known about its timing,
the changes in the clonal composition over time, and the degree
of independent evolution between primary tumour and
metastases.
To study the events driving osteosarcomagenesis, here, we
focus on the clonal dynamics that occur during the formation,
development, and progression of a murine model of in vitro
transformed mesenchymal progenitor cells (MPCs). We pre-
viously reported the transformation of MPCs by deleting the
Tp53 and Rb genes. These MPCs, if inoculated in the proper
orthotopic or ectopic ceramic-based osteoinductive micro-
environment, efficiently recapitulate OS formation34. In this
study, we used a single-cell tracking technique to study the in vivo
OS clonal dynamics during tumour formation and progression.
Based on lentiviral transduction with vectors coding for three
different fluorescent proteins (Cerulean, Venus, and Cherry) as a
marking approach (Lenti LeGO-RGB vectors), we developed a
protocol in which each individual OS cell displays a different
colour of the rainbow spectrum. These cells were used to inter-
rogate the clonal evolution-related questions in in vivo ortho-
topic, ectopic, and metastatic tumourigenesis studies. In our
studies we show that osteosarcomagenesis can follow a neutral
evolution model; different clones can coexist and propagate over
time and only some of them become locally dominant invading
the adjacent microenvironment. Metastatic disease also presents
signs of polyclonality, where metastatic clones can be distinct
from the dominant clones present in the primary tumour. In
summary, our study offers an overview of the clonal dynamics in
OS development.
Results
Efficient and stable RGB marking of murine MPCs. To gen-
erate RGB (red–green–blue) multi-coloured cells, we used three
lentiviral vectors Cherry (red), Venus (green), and Cerulean
(blue), which express different fluorescent proteins. The RGB
marking of murine p53−/−Rb−/− bone marrow-derived MPCs
(BM-MPCs) was achieved by transducing cells with multiplicity
of infection (MOI) corresponding to equimolar transduction
efficiency per vector of 50%. Correct cell line transduction was
validated based on fluorescent colour saturation and the varia-
bility of colour mixing. As verified by confocal microscopy, an
optimal colour spectrum was obtained using an MOI of 0.75 per
vector, whereas excessively high MOIs resulted in poor colour
mixing (Supplementary Figure 1a). These multi-coloured cells,
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designated RAINBONE cells in this text, showed a wide range of
colours, with each colour representing a different clone (Fig. 1a).
To optimize flow cytometry analysis, monoclonal cell lines were
obtained by the limiting dilution of RAINBONE cells, and an
oligoclonal mix was further generated by mixing six of these
monoclonal lines. As shown in Supplementary Figure 1b, each
monoclonal cell line presented a narrow peak of fluorescence,
whereas the oligoclonal mix was composed of a combination of
discrete peaks (Supplementary Figure 1c). In contrast, polyclonal
RAINBONE cells displayed a broad fluorescent distribution
generated by the integration of signals from a multitude of clonal
populations (Supplementary Figure 1d). Three-dimensional (3D)
visualization, which was accomplished by plotting the three
fluorescent variables in a Cartesian plot (x,y,z), or 3D plot,
increased clonal discrimination. Thus, monoclonal or oligoclonal
cell lines could be easily identified, whereas heterogeneous
RAINBONE cells covered the three axes and their possible
fluorescent colour combinations.
Clonal heterogeneity and the stability of fluorescent markers of
RAINBONE cells were studied and quantified during 50 days of
in vitro culture by flow cytometry (Supplementary Figure 2;
Fig. 1b, c). Visual stochastic network embedding (viSNE)
(Supplementary Figure 3a) and spanning-tree progression
analysis of density-normalized events (SPADE) (Supplementary
Movie 1) were also applied to study clonal heterogeneity over
time. Our results showed that the multicolour spectrum of
RAINBONE cells was stable and that clonal heterogeneity was
maintained during in vitro culture.
Tumour heterogeneity in osteosarcomas. It was previously
shown that murine p53−/−Rb−/− BM-MPCs can generate OS if
implanted ectopically in the proper osteoinductive micro-
environment34. Therefore, we tested the nature of subclonal
interaction in tumour growth. RAINBONE cells were further
transduced with an ff-Luciferase lentiviral vector, and unmarked
p53−/−Rb−/− BM-MPCs were also transduced to calculate an
optimal MOI and obtain >80% transduction efficiency (Supple-
mentary Figure 4). Limiting dilution clones obtained with
RAINBONE cells and a clonal mix of increasing clonal compo-
sition were embedded in ceramic scaffolds and implanted sub-
cutaneously in vivo in NOD.Cg-Prkdcscid-Il2rgtm1Wjl/SzJ
(NSG) mice; luciferase activity was used to directly quantify
tumourigenicity and tumour growth kinetics (Supplementary
Figure 5a). Seven out of 7 randomly selected monoclonal cell lines
were tumourigenic (100% incidence), further revealing a tendency
to grow faster if compared to OS generated by a clonal mixture of
either 5 or 10 different limiting dilution clones or the pool of
RAINBONE cells. Overall, OS tumour growth was slower at
increasing clonal complexity and each clone shows a hetero-
geneous growth kinetic if implanted alone. Furthermore, around
40% of RAINBONE cells formed colonies at in vitro cell trans-
formation assays (Supplementary Figure 5b).
In summary, this experiment confirmed the competitive nature
of subclonal populations and further indicated that the Ad-Cre
deletion of Tp53 and Rb is a strong transforming event for murine
MPCs which are composed of a pool of heterogeneous
transformed cells.
Given their competitive nature, the clonal composition of
RAINBONE-generated OS was studied in vivo for short (25 days)
and long (50 days) periods. An experimental workflow schematic
is shown in Fig. 2a. After 25 days, RAINBONE cells developed
tumour masses with highly vascularized areas surrounding the
ceramics. Histologically, tumours developed heterogeneously,
with both rich bone matrix deposition areas and fibroblastic
regions (Fig. 2b). At this stage of development, tumour cells
showed no clonal dominance by flow cytometry (Fig. 2c) or
confocal studies (Fig. 2d, e and Supplementary Figure 6a).
Instead, tumours were characterized by large areas of multi-
coloured cells suggesting a polyclonal composition. viSNE
(Supplementary Figure 3b) and SPADE analysis (Supplementary
Figure 3c) also confirmed clonal heterogeneity. Genome insertion
site analysis by linear amplification-mediated polymerase chain
reaction (LAM-PCR) indicated strong amplification of different
long terminal repeat (LTR)-genome junctions (Fig. 2f and
Supplementary Figure 7), further supporting a polyclonal tumour
composition. Spectral karyotyping (SKY) analysis identified a
high level of genomic heterogeneity among cancer cells, which
presented a tetraploid karyotype with high levels of aneuploidy,
some large deletions, and non-clonal translocations (Supplemen-
tary Figure 8 and Supplementary Table 1).
In summary, our data demonstrate that at an early stage, OS
can be composed of coexistent, heterogeneous, competing cancer
populations. However, this competition is not associated with a
strong clonally selective event.
Clonal evolution in osteosarcoma progression. To further
explore the dynamics of OS progression, we extended tumour
development and clonal studies. In contrast to the previous
results, RAINBONE tumours showed changes in their clonal
growth after a longer period (50 days). The central tumour mass
maintained a polyclonal composition, but the tumour periphery
showed abundant expansion of a few clones (Fig. 3a and Sup-
plementary Figure 6b). A heterogeneous clonal composition was
confirmed by LAM-PCR (Fig. 3c and Supplementary Figure 7),
and flow cytometry detected the enrichment of some discrete
populations. This result was also confirmed by SPADE and
viSNE analysis (Fig. 3e and Supplementary Figure 3b–c). His-
tologically, extracompartmental areas showed increased cellu-
larity with scant bone matrix deposition, whereas an osteogenic
phenotype was maintained in the ceramic region (Supplemen-
tary Figure 6b). Of note, clones having the ability to grow
outside the ceramic region were different in each animal tumour
(Fig. 3e). Despite these areas being apparently monoclonal, a few
clones could also be identified, supporting the heterogeneous
nature of these regions (Fig. 3d). Explanted tumour cells from
these peripheral regions were sorted by fluorescence-activated
cell sorting (FACS) based on their fluorescence fingerprint
(Fig. 3f). As expected, these clones showed a few discrete
insertion sites in a pattern similar to the control monoclonal
populations obtained by in vitro limiting dilution (Fig. 3g;
Supplementary Figure 7 and Supplementary Table 2). SKY
analysis identified high genomic heterogeneity among cancer
cells even when they were of monoclonal origin (Supplementary
Figure 8 and Supplementary Table 1). Additionally, for these
clones, the clone-to-clone relationship presented a competitive
nature; 4 out of 4 monoclonal tumours in secondary trans-
plantation exhibit faster growth compared to an oligoclonal mix
composed of the previous tumour (Supplementary Figure 5c).
However, subclonal competition did not lead to clonal extinc-
tion; all clones remained present, as indicated by flow cytometry
analysis (Supplementary Figure 5d–left). Three out of 4 oligo-
clonal tumours showed the dominance of the G11 clone (tur-
quoise arrow), whereas one tumour was mostly formed by the
R7 population (pink arrow), which surprisingly showed faster
growth when implanted alone (Supplementary Figure 5c). Fur-
thermore, in vitro growth assays indicated that in experimental
conditions with no space competition and an equal nutrient
supply, the R9 clones grew faster (Supplementary Figure 5d–
right); nevertheless, this clone was infrequently identified in the
in vivo assay (Supplementary Figure 5d–left).
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In summary, these experiments demonstrate that clonal
evolution is associated with the ability to grow in a new
microenvironment at a late stage of disease. Furthermore, this
phenotype is acquired by different dominant clones that present
karyotypic heterogeneity and different in vitro or in vivo growth
rates. In this case, we confirmed a regional and selective clonal
dominance while a highly polyclonal area remains present.
Neutral and selective dynamics of orthotopic OS development.
Tumour formation at the orthotopic site by our experimental
p53−/−Rb−/− BM-MPCs was previously demonstrated to effi-
ciently recapitulate the main features of OS, including metastatic
disease34. Therefore, RAINBONE cells were also inoculated in the
proximal tibia of immunodeficient mice, and tumour develop-
ment was evaluated by bioluminescence and X-ray imaging. Mice
showed radiographic characteristics compatible with intrame-
dullar bone deposition and cortical bone osteolysis (Fig. 4a, d). At
50 days after RAINBONE cells were implanted, mice were killed
due to limb function loss. Confocal microscopy indicated great
colour heterogeneity in the tumour. Cells of different clonal
origins were found in the medullar space infiltrating the compact
bone, growing at the endosteum, and even as sparse single cells at
perivascular locations (Fig. 4b). Increased pseudo-trabecular bone
formation was promoted by cells of different clonal origins and
also evidenced by colourful osteoblastic rimming (Fig. 4c). In
some mice, tumours produced a strong periosteal reaction with
structures resembling Codman triangles and presented a soft
tissue mass development over the bone surface (Fig. 4d). These
areas were composed of few dominant clones with increased
invasiveness of the adjacent musculoskeletal tissues (Fig. 4e).
Tumours frequently destroyed the metaphyseal plate (Fig. 4f) and
developed outside of the medullar cavity in large monoclonal
globular-shaped soft tissue masses, which also presented low-
frequency infiltrating clones of different clonal origins (Fig. 4e, g).
Altogether, the results suggest that clonal heterogeneity is a
common growth dynamic in our OS models and that there are
signs of clonal evolution in the late phases, a characteristic that is
primarily associated with the ability to grow in a new
microenvironment. Furthermore, we show that orthotopic and
osteoinductive ectopic models do not differ substantially in terms
of clonal evolution; each develops some clones that are able to
expand extracompartmentally in late-stage disease.
Metastatic disease is driven by polyclonal seeding of lungs.
Bioluminescent and X-ray imaging were employed in the ortho-
topic model as diagnostic high-sensitivity techniques. Biolumi-
nescence revealed the formation of multiple metastatic nodules in
the lungs, and this was further confirmed by histological analysis
(Fig. 5a and Supplementary Figure 6c). Metastatic dissemination
appeared heterogeneous, with different clonal development
dynamics. Metastases were usually heterogeneous, presenting
different sizes and clonal origins (Fig. 5b). In total, 146 metastases
were quantified for monoclonality or oligoclonality and measured
(Fig. 5c). Monoclonal seeding was more frequent; however,
excluding small micrometastases (<200 µm), which could repre-
sent a dormant state, the nodules showing significant growth were
both monoclonal and oligoclonal (Fig. 5d). Furthermore, meta-
static clones did not correspond to the dominant clones present
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Fig. 1 RGB marking of RAINBONE cells is stable during in vitro culture. a Representative confocal microscopy image of the optimal colour mixture. Orange
bar= 100 µm. b Representative 3D flow cytometry analysis of RAINBONE cells at day 0 (left) and day 50 (right) of in vitro culture. c Quantification of the
fluorescent distribution during 50 days of in vitro culture
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Assuming that heterogeneous nodules could originate from the
lung homing of a cluster of cells or by secondary clones homing
into a pre-existing nodule, we decided to test the ability of in vivo
tested metastatic clones (Supplementary Figure 9b) to seed pre-
existing metastases. We induced RAINBONE tumours, and
bioluminescence was used to follow tumour growth and effective
lung engraftment (Fig. 5f). Individual metastatic clones were
inoculated intravenously (i.v.) when there was evidence of
spontaneous metastatic disease (50 days). After 10 days of i.v.
inoculation, lungs were dissected and processed for confocal
studies. Only four out of 75 (5.3%) lung metastatic nodules
analysed presented the characteristic fluorescent fingerprint of the
i.v. inoculated clones, indicating the low homing ability of
metastatic clones into pre-existing metastatic lung nodules
(Fig. 5g).
Our data indicate that metastatic disease is highly hetero-
geneous and that different clones develop in the lungs with signs
of polyclonal seeding. Moreover, the aggressiveness of dominant


























































Fig. 2 RAINBONE cells generate polyclonal tumours in ectopic implants. a Experimental scheme employed for ectopic OS development (n= 7).
b Haematoxylin/eosin staining (HE) staining of tumours generated by ectopically implanted cells. Spindled cells produced abundant bone matrix (+) near
HA/TCP ceramics (*). c Representative 3D flow cytometry analysis of in vitro RAINBONE cells (left) and explanted tumour cells at day 25 (right) (n= 3).
d Representative confocal images showing the colour spectra of different in vivo tumour clones. e Representative confocal macroscopic view of polyclonal
RAINBONE tumours indicating the contribution of different clones to tumour generation; orange bars= 100 µm. f LAM-PCR analysis showing the
amplification of different provirus integration sites in RAINBONE tumours. Picture represents the same gel; vertical lines were added where non-
informative lanes were excised. Horizontal yellow lines demarcate the standard size range of the PCR products to exclude amplification artefacts. Negative
control=water, WT tumour= tumour generated by unmarked cells
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Dominant clones are composed of homogeneous subclones. As
described above, RAINBONE tumours induced subcutaneously in
osteogenic implants present spatially dominant clone develop-
ment at late-stage disease (50 days). We wanted to study the
grade of heterogeneity of these dominant clones, including the
hypothetical presence of cancer stem cells responsible for sus-
taining tumour repopulation. Therefore, we designed an experi-
ment (Fig. 6a) in which dominant clones were sorted by FACS
and monoclonal populations were established (Fig. 6b, c); three
populations were further decoloured using adenoviral vectors
expressing Cre recombinase. Fluorescent marker loss was assessed
by flow cytometry (Fig. 6d), and we did not observe resistance to
Ad-Cre recombination; three out of 3 clones showed almost pure
fluorescent marker loss (Supplementary Figure 10 and Supple-
mentary Table 3). Decoloured cells underwent a second round of
RGB colouring using lentiviral Gene Ontology (LeGO)-RGB
lentiviral vectors, generating RAINBONE-2 cells (Fig. 6e, f),
which were implanted in NSG mice. In these secondary tumours,
we observed a strong reduction in bone matrix content and faster
tumour development (15 days) compared to primary RAIN-
BONE tumours. Confocal study and flow cytometry with sec-
ondary tumours showed a polyclonal contribution to tumour
development (Fig. 6g, h). Then, RAINBONE-2 explanted cells
underwent further tertiary transplantation in NSG mice. Again,
these tertiary tumours showed the same polyclonal heterogeneity
(Fig. 6i, j). The viSNE and SPADE analysis also confirmed the
heterogeneous subclonal composition (Supplementary Figure 11).
Our results indicate that dominant clones are formed by a
homogeneous equilibrium of subclones with similar tumour
regeneration potential.
Discussion
Single-cell studies and massive genome sequencing techniques
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Fig. 3 RAINBONE tumours showed dominant clones in the long term. a Representative image of tumours 50 days after RAINBONE inoculation (n= 14). 1,
Primary implantation site (HA/TCP ceramic region) showing polyclonal evolution; 2, transition zone; 3, large monoclonal areas generated outside of the
ceramic region (extracompartmental region). b For comparison, representative image of tumours at 25 days, with tumour growth starting in the
extracompartmental region. c LAM-PCR analysis showing the rich amplification of different provirus integration sites in both short- and long-term
RAINBONE tumours. Negative control=water. d Representative detailed image of tumour heterogeneity present in the large clonal area. Low-frequency
clones are indicated by white arrows. e Representative SPADE tree clonal composition of RAINBONE tumours at 50 days. Note that in this case, colours
represent the population frequency. f Representative 3D flow cytometric RAINBONE tumour analysis at 50 days (n= 4). Arrows indicate the most
frequent clones that were subsequently FACS sorted (right). g LAM-PCR analysis showing the monoclonal origin of FACS sorted clones (n= 3). White
bar= 200 µm; orange bar= 100 µm; blue bar= 50 µm
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of these studies provide better understanding of cancer as a
heterogeneous disease and highlight differences in the growth
patterns of specific tumour types. Here, we used a single-cell
tracking technique based on fluorescent protein expression using
lentiviral vectors (Lenti LeGO-RGB vectors). Due to the variety of
integration sites and vector copy number, when these vectors are
used in the appropriate combination, they mark each individual
cell with a different colour of the rainbow spectrum that is then
transmitted to derived progeny. This technology is a powerful
tool for clonal cell studies in vitro and in vivo35–37 as it represents
an unbiased approach for studying tumour physiology; it does not
require any preselected marker and allows the direct study of
tumour clones and progeny in the spatial organization of the
tissue. Lenti LeGO-RGB marking has been successfully used to
clonally track in vivo metastatic mammary adenocarcinoma38,
pancreatic adenocarcinoma39, and neuroendocrine carcinoma35,
and it has also been used in combination with mass
spectrometry39.
These findings support the value of RGB marking in tumour
heterogeneity studies. However, this approach has only been tested
in well-established carcinoma cell lines. Murine p53−/−Rb−/−
BM-MPCs employed for generating RAINBONE cells were not
isolated from pre-existing tumours but were transformed in vitro
prior to inoculation into mice. Our double-hit model allows
murine cell transformation with the establishment of a hetero-
geneous cell population of transformed MPCs. In our conditions,
RAINBONE cells present malignant features and are efficiently
transformed by p53 and Rb loss. This result is in contrast with
previous studies reporting a low tumour-initiating potential for
mesenchymal lineage cells. However, in our studies we employed
severe immunodeficient NSG mice and implanted cells in an
orthotopic and ectopic bone-like microenvironment, thus
excluding some of the harsh conditions that most likely affected
other studies. Indeed, the tumour-initiating cell frequency of
melanoma cells can reach 25% of the total population when using
a cell matrix or less immunocompetent mice40. Given the high
tumour-initiating potential, our model represents a powerful tool
to test the cohabitation of different cancer clones and the possible
dynamics of competition among them (see further discussion
below). Our artificial condition represents a model with which we
can test clonal evolution, the existence of selective events, or even
the neutral dynamics of growth. Furthermore, these cells hypo-
thetically have not been shaped by the tumour microenvironment
and have never experienced the growth dynamics and selective
pressure occurring during in vivo tumour development. All these
characteristics make RAINBONE cells an interesting model of
in vivo primary tumour generation, allowing us to test different
hypotheses about clonal dynamics and dispersal forces occurring
during osteosarcomagenesis.
Our experience with RGB marking is that it represents a very
powerful technology; nevertheless, some technical difficulties
















Fig. 4 Orthotopically implanted RAINBONE cells generate polyclonal tumours. a Tumour developing in the medullar space (orange arrow). Blue section
indicates the visual plane for haematoxylin/eosin staining (HE) and confocal images. XR X-ray imaging. b Representative image of RAINBONE cells located
in the endosteal space, at perivascular locations, and in compact bone (white arrows). c Detail view of picture B (Box 1) showing osteoblastic rimming (*)
and malignant trabecular bone (+). d Osteolytic tumour overgrowing as a soft tissue mass at 50 days presented strong periosteal reaction and a Codman
triangle (orange arrows). e Representative image of a large bi-clonal area growing on the outer surface of bone; two different dominant clones are
developing in opposition (white line indicates the border limits). f Detailed view of cartilage plate infiltration and destruction. g Picture detail (Box 2) of the
clonal growth in the surrounding of musculoskeletal tissue, with low-frequency clones (white arrow) among larger monoclonal areas. White and black
bars= 200 µm; blue bars= 50 µm; n= 5
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specific monoclonal population by FACS sorting RAINBONE
tumours. This limitation, produced by a loss of definition in flow
cytometric data, was due to the equal representation of different
clonal populations with overlapping flow cytometric fingerprints.
Furthermore, in some cases it was difficult to obtain a pure clonal
sorting, and some very low-frequency clones of different colours
appeared in culture. We tried different flow cytometers, services,
and users, and we solved this problem by resorting clones after a
short in vitro amplification. We rationalized that sorting multiple
clonal populations at the same time can affect process efficiency
and purity. In conclusion, with the employment of different
microscopic and genetic techniques, we avoided the
misinterpretation of results, and the technical limitations did not
greatly hinder the main objective of the study.
In evolutionary theories, competition is a long and steady
principle that is continuously occurring in ecological systems,
such as cancer41,42. From an early stage of cancer development,
tumour cells compete for limited resources (nutrients and oxy-
gen) to the point of saturation21 and encounter a strongly
selective microenvironment (pH changes, immune system, geo-
graphic barriers, and chemotherapy) that further limits their
development14. In this context, dispersal forces could also play a
key role in tumour progression;43 populations of spreading cells





























































































Fig. 5 RAINBONE cells generate monoclonal and polyclonal lung metastases. a Orthotopic OS tumours generated lung metastasis (n= 5, same mice from
the previous experiment) that was detected by haematoxylin/eosin staining (HE), X-ray (XR), and bioluminescent imaging. Orange arrows indicate ossified
lung metastasis. b Representative image of RAINBONE lung metastases showing nodules of different colours and composition; monoclonal (+) and
oligoclonal (*) nodules. c Representative images of oligoclonal and monoclonal nodules and size heterogeneity. d Quantification of metastatic nodules
(n= 146) according to monoclonality and polyclonality (left graph, P value= 0.0497) and further categorized depending on their size (right graph,
P values= 0.396). Statistic tests: two-tail paired t-test and two-way ANOVA, Bonferroni post hoc test, CI: 95%, alpha: 0.05. P < 0.05. In boxplot graphs
centre line indicates median, bounds of box indicate 25th and 75th percentiles, and whiskers indicate minimum and maximum. e Representative SPADE
tree clonal composition of explanted primary tumour (left) and lung cells (right). In this case, colour represents the population frequency. f Bioluminescent
in vivo growth quantification of primary tumours (n= 5, new experimental group) and lung metastases (n= 4). One animal did not develop metastatic
disease (dotted line). The black arrow indicates intravenous inoculation of monoclonal FACS sorted clones in reseeding experiments (50 days). The
average radiance was normalized to the bioluminescent signal 4 h after inoculation (day 0); data are presented as the means and the error bars represent
the maximum and minimum values per group. g From the left to the right: representative confocal image of in vitro FACS clones, cells (blue arrows) after 4
h of i.v. inoculation, and two different reseeded metastases at day 60; for those appearing in colour, a further colocalization study was performed. Yellow
bar= 500 µm; white bar= 200 µm; blue bar= 50 µm
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competitors and thus reducing cell–cell interaction44. Dispersal
forces could also explain the metastatic process, a paradoxical
outcome of tumour evolution that is not related to cell survival
the way that other tumour hallmarks are (apoptosis, immune
evasion, etc.)45,46. The main basis of the neutral theory is the
neutral outcome of this process of competition, in which different
species (cancer clones) mainly coexist and the acquisition of new
genomic traits is mostly neutral. This model contrasts with the
reiterative positive selection postulated by the Darwinian model
of evolution. According to the Darwinian model, the acquisition
of new phenotypic traits gives an increased replicative fitness to a
new species with the continuous extinction of the unfit ones.
Nevertheless, the neutral and competitive models are not com-
pletely in antithesis, and neutral evolution also allows positive
selection27,47. The difference between the two models is mostly
concerning the frequency of the positive selective events, which
are defined as rare in the neutral theory. Positive selection is
mostly relegated to strong microenvironmental changes, che-
motherapy, immunotherapy, metastatic spread, and during the
first stage of tumour evolution27,48. Therefore, after the accu-
mulation of genomic alteration that initiates tumour growth,
cancer cells expand neutrally and accumulate extensive genomic
heterogeneity.
In line with the neutral model, within a short time of tumour
evolution (25 days), OS tumours systemically presented histolo-
gical heterogeneity together with a polyclonal distribution of
tumour cells, thus not resembling a strongly selective linear
model of clonal cancer evolution16. As in Nature, clonal com-
petition is also occurring in our model, in which the dynamics of
competition among cancer clones represent forces able to slow
down tumour growth. Nevertheless, the outcome of this com-
petition is not resulting in clonal selection. We observed that
different clones characterized by high genomic heterogeneity
contributed with proliferating or differentiating cells in the
tumour (Fig. 7a). This behaviour is in agreement with a neutral
evolution pattern and lacks evidence of a real selective advantage
gain. In contrast, at late-stage evolution (50 days), tumours
showed a different organization; large extracompartmental
monoclonal areas arose adjacent to the osteoinductive area gen-
erated in the hydroxyapatite/tricalcium phosphate (HA/TCP)
compartment, presumably as a consequence of the effective
pressure for clonal selection caused by different microenviron-
mental conditions. In this sense, clonal selection seems to be
mostly associated with an adaptation to new specific spatial/
microenvironmental determinants (Fig. 7a). It is important to
consider that one parameter in the staging system of muscu-
loskeletal tumours is the ability to grow extracompartmentally,
which is also associated with a worse prognosis.
The fact that different clones within the same tumour are able
to grow extracompartmentally provides evidence of a parallel
evolution model among cancer cells. Additionally, in agreement
with a contingency evolution context, our data suggest that
starting from a pool of transformed cells, the chance of becoming
a clone with this phenotype is not pre-established but that con-
straints can lead to convergence on this possible outcome. In fact,
each specific tumour in each animal shows different dominant
clones. Karyotype analysis of these clonal populations revealed
extended karyotype variability among cells, which is compatible
with a divergent pathway of cancer evolution and in accord with
branched models. At the subclonal level, these cells show a high
tumour-initiating potential, which is also in agreement with a
secondary and tertiary level of coexistence (Fig. 7a). However, it is
common to observe low-frequency clones infiltrating the domi-

















































Fig. 6 Isolated clones from RAINBONE tumours regenerate polyclonal tumours. a Experimental design of RAINBONE subclone recolouring and their in vivo
tumourigenic potential (secondary n= 9, tertiary n= 9). The 3D flow cytometry analysis (b) and confocal image (c) of representative RAINBONE FACS
sorted clones (n= 3). d Representative 3D flow cytometry analysis of decoloured clones after Ad-Cre transduction. Representative 3D flow cytometry
analysis (e) and confocal microscopy image (f) of RGB-marked (recoloured) FACS sorted clones (RAINBONE-2). Representative 3D flow cytometry
analysis (g) and confocal microscopy image (h) of RAINBONE-2 tumours (15 days of secondary transplantation) showing a polyclonal population.
Representative 3D flow cytometry analysis (i) and confocal microscopy image (j) of RAINBONE-2 tumours (15 days after tertiary transplantation) again
showing a polyclonal contribution. Blue bars= 50 µm
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which adds a new level of heterogeneity. This type of pattern
strongly resembles the dynamics of collaboration and/or para-
sitism that were proposed in other reports49.
In summary, our study demonstrates that different dynamics
simultaneously participate during tumour evolution, but we
support the idea that the clinical relevance of tumour evolution
should not be restricted only to dominant clones. In support of
this concept, a clinical report in osteosarcoma described how
some low-frequency clones detected at diagnosis could be
responsible for tumour relapse, thus underlining the importance
of low-frequency populations of cancer cells and the less fruitful
branches of tumour evolution50.
Metastatic seeding is another malignant feature of OS disease
that can follow different dynamics. Some interesting reports, also
employing multicolour lineage tracing, have started to highlight
unknown mechanisms occurring during metastatic dissemina-
tion. Thus, the monoclonal or polyclonal dynamics of metastatic
spread, collective dissemination, and reseeding were reported in
different models of carcinomas51–53. Interestingly, some authors
demonstrated that clonal cooperativity in cancer dissemination
may play a primary role in improving the chances of engraftment
at distant sites. In a model of pancreatic cancer, polyclonal
clusters of cancer cells actively colonized distant organs, repre-
senting a cooperative strategy, and a reduction of cluster forma-
tion also reduced metastatic potential45. In our OS model, we
observed the development of different monochromatic and oli-
gochromatic nodules, in accord with a polyclonal seeding
(Fig. 7b), and a parallel progression model in lung colonization.
Furthermore, the existence of oligoclonal metastases raises new
questions about their origin and their intermetastatic subclonal
dynamics because different clones can still coexist. Given the
inefficiency of metastatic clones to home in pre-existing metas-
tases, oligoclonal nodules do not seem to be the outcome of a
secondary seeding wave, or reseeding (Fig. 7b). This result could
be explained by the existence of a local microenvironment that
allows the homing of monoclonal or oligoclonal seeds at the
beginning of the disease and that impedes the engraftment of new
clones once perturbed. In summary, our data question the com-
petitive linear model in metastatic evolution and indicate that
clonal dynamics occurring in metastatic disease do not differ
from the dynamics at the primary site.
In conclusion, tumour evolution is thought to be caused by
clonal competition and selection, which would lead to aggressive
clone development in the fight for the survival of the fittest. By
contrast, we present evidence that osteosarcomagenesis can fol-
low the dynamics of neutral evolution, in which different cancer
clones coexist and propagate simultaneously over time. Clonal
biodiversity seems to be an important feature in our model. This
equilibrium is maintained until the disease progresses to a more
































Fig. 7 Schematic representation of the clonal dynamics in osteosarcomagenesis. a Schematic model of ectopic OS generated by transformed MPCs; the
model indicates clonal heterogeneity over time; the first level of neutral evolution is typical of tumours at 25 days of development; clonal equilibrium is
maintained until the development of different locally dominant clones in the extracompartmental region at 50 days. Dominant clones are sub-clonally
heterogeneous and establish tumour development through a new level of neutral coexistence in secondary and tertiary transplantation. b Schematic model
of OS developing at orthotopic location (left) and metastatic disease (right). Note the clonal heterogeneity in the medullary space and the outgrowth of
locally dominant clones (one is depicted for simplification). On the right, the possible clonal dynamics of metastatic seeding are indicated; changes in
colonization strategy (single cells vs. cluster), evolution models (selection vs. parallel vs. neutralism), clonality (monoclonality vs. polyclonality), and timing
(synchronous vs. asynchronous) of the process are indicators of the possible clonal origin and the final clonal composition of metastatic nodules. Our
model presents evidence of parallel evolution and polyclonal synchronous seeding dynamics
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06401-z
10 NATURE COMMUNICATIONS |  (2018) 9:3994 | DOI: 10.1038/s41467-018-06401-z | www.nature.com/naturecommunications
microenvironment where dominant clones appear. Distant lung
polyclonal seeding also results in the spatial dominance of many
clones, which can be distinct from the dominant clones in the
primary tumour. In summary, our study offers an overview of the
clonal dynamics and relevance of dispersal forces in OS devel-
opment; this knowledge is useful for understanding tumour
biology and may improve clinical practice and therapeutic design.
Methods
Cell lines. Murine BM-MPCs were isolated from transgenic FVB mice bearing Tp53
and Rb genes flanked by LoxP sites. Gene deletion was achieved in vitro by the
adenoviral transduction of Cre recombinase gene under the control of cytomega-
lovirus promoter to obtain transformed p53−/−Rb−/− BM-MPCs. Successful gene
knockdown was confirmed by genomic PCR and western blot34. p53−/−Rb−/− BM-
MPCs underwent lentiviral RGB marking in vitro. Cells were maintained in Dul-
becco’s modified Eagle’s medium supplemented with 10% foetal bovine serum, 1%
penicillin/streptomycin, and 1% Glutamax and were routinely tested for myco-
plasma presence (MycoAlert-Mycoplasma Detection kit, LONZA).
RGB lentiviral vectors and RGB multicolour marking. LeGO-RGB lentiviral
vectors were used as colour-guided clonal cell trackers. LeGO vectors were kindly
provided by Dr. Kristoffer Riecken, University Medical Center Hamburg,
Germany36,37,54. LeGO-Cer2 (Addgene: 27388), LeGO-V2 (Addgene: 27340), and
LeGO-C2 (Addgene: 27339) plasmids were employed to produce lentiviral vectors
coding for blue, green, and red fluorescent proteins, respectively. Supernatant was
collected 48 h after transfection and concentrated by ultracentrifugation. Lentiviral
particle mixtures were added to the p53−/−Rb−/− BM-MPCs and incubated
overnight to generate RGB multicolour-marked murine p53−/−Rb−/− BM-MPCs,
which were named RAINBONE cells. The RGB colour mix was achieved using a
MOI of 0.75, which corresponds to an equimolar transduction efficiency of 50%
per lentiviral vector 3 days after transduction. Six monoclonal cell lines were
derived from RAINBONE cells by in vitro limiting dilutions. Single-cell plating
efficiency and clonal purity were assessed by confocal fluorescence microscopy and
flow cytometry, respectively. LeGO-RGB vectors also contain additional loxP sites
which allow the elimination of fluorescent proteins using a Cre recombinase. Three
different FACS sorted RAINBONE clones were decoloured by the in vitro ade-
noviral transduction of Cre recombinase. Decoloured clones underwent lentiviral
recolouring. These recoloured clonal populations represent the RAINBONE-2 cells
that underwent secondary and tertiary in vivo tumour generation.
Flow cytometry analysis and cell sorting. Cells were resuspended in phosphate-
buffer saline (PBS) for flow cytometric study. Fluorescence signal distribution was
analysed using a BD LSRFortessa (BD Bioscience) cell analyser. Cerulean fluor-
escent protein was excited at 405 nm and detected with a 450/50 bandpass filter,
Venus was excited at 488 nm and detected with a 530/30 bandpass filter, and
Cherry was excited at 561 nm and detected with a 610/20 bandpass filter. Discrete
cell populations developed in osteogenic implants were further sorted using a iCyt
SY3200 Cell Sorter (SONY). Cerulean fluorescent protein was excited at 405 nm
and detected with a 525/50 bandpass filter, Venus was excited at 488 nm and
detected with a 525/50 bandpass filter, and Cherry was excited at 532 nm and
detected with a 615/30 bandpass filter. Sorted populations were expanded in vitro
for a short period, and sorting purity was verified by flow cytometry and confocal
microscopy. Flow cytometry data were analysed with FlowJO software (FlowJo
LLC).
Unsupervised visualization analysis of clonal architecture. FCS files were loa-
ded in the Cytobank website (https://premium.cytobank.org) to perform different
types of unsupervised analysis of the clonal architecture of the samples. Samples
were gated to analyse the mononuclear cell fraction. The clustering of sample
events was performed, taking into account only the intensity of Cerulean, Venus,
and Cherry channels. For this aim, a viSNE map was generated; this approach uses
t-distributed stochastic neighbour embedding (t-SNE) algorithms55. The generated
results are provided in two-dimensional scatter plots and show the intensity of the
three fluorescent channels analysed. A SPADE algorithm was used to extract
population hierarchies and visualize individual clones in a tree-like structure56.
SPADE performs density-dependent down-sampling to equally represent rare and
abundant populations and then performs agglomerative clustering while taking
into account the intensity of selected channels. In this case, SPADE was used to
cluster and represent the data as 200 different clones.
Fluorescent microscopy analysis. In vitro confocal microscopic studies of
RAINBONE cells were performed by seeding cells in multichambers. After over-
night incubation, slides were washed with PBS and fixed with 4% formalin or 1%
paraformaldehyde (PFA) for 1 min. After fixation, slides were washed again with
PBS and mounted with ProLong. In the case of explanted primary tumours and
lungs, samples were processed for histologic staining and confocal fluorescence
analysis by cryosectioning. Samples were fixed overnight in 4% formalin or 1% PFA
and decalcified for 72 h prior to inclusion in optimal cutting temperature Tissue-
Tek. All processes were performed in the dark at room temperature. The 8 µm
slides were defrosted and stained according to histologic standards or pre-warmed,
hydrated in PBS for 2 min, and then mounted using ProLong for confocal
microscopy studies. A confocal multispectral TCS-SP5 (Leica Microsystems)
microscope was employed in this study. Representative images were obtained by
maximum projection of a 10-layer stack of 8 µm-thick sections. Images were
processed using LAS AF (Leica Microsystems). For lung seeding quantification,
metastatic nodules were screened to identify the fluorescent fingerprint of i.v.
inoculated FACS clones. A colocalization study was performed with ImageJ to
ensure the presence of fluorescent markers specific to the inoculated clone and to
exclude ambiguous cells. Macroscopic fluorescence and/or brightfield image maps
were acquired with TCS-SP5 (Leica Microsystems) and AxioScan.Z1 (Zeiss). LAS
AF and ZEN 2.3 (blue edition) were employed for image processing.
Mouse models. All procedures and animal care were performed at the National
Institute of Health Carlos III (ISCIII) with the approval of the Institutional Animal
Research and Welfare Ethics Committee according to the EU Directive for animal
experiments in a specific pathogen-free environment. Experiments were performed
using 8–10-week-old NSG mice. A minimum sample size of 4 mice per each
experimental group was established; this size was chosen in accordance with 3 Rs
(Replacement, Reduction, and Refinement) rule for animal experimentation,
ensuring sufficient statistical power in dichotomous studies. Inclusion or exclusion
criteria were pre-established and represent the physiological status of the animal at
final experimental point. OS development was induced using two different pro-
cedures. For the orthotopic inoculation into the bone marrow space of the prox-
imal tibia, cells were resuspended in PBS, filtered through a 70 µm nylon filter, and
concentrated to 7.5 × 106 cells/ml. Surgery was performed by bending the mouse
leg at 90° to drill the tip of the tibia with a 25 G needle and depositing the cell
suspension in the medullar space (1.5 × 105 cells/mouse) with a 27 G needle. For
ectopic osteogenic implants, 40 mg of ceramic powder (60% hydroxyapatite/40%
tricalcium phosphate beta) with a surface microporosity less than 10 μm (Bio-
matlante) was deposited in a 50-ml falcon tube and washed with 1 ml of culture
medium. The cell suspension was mixed with ceramic powder (1.5 × 105/implant),
centrifuged at 1200 rpm for 5 min in a centrifuge with a swinging bucket rotor, and
incubated overnight. Culture medium was carefully removed, and cells with
ceramic powder were bound in a fibrin clot for subcutaneous implantation34. For
bioluminescent studies, RAINBONE cells were transduced at MOI 5 with lentiviral
particles carrying the firefly luciferase gene. Lentiviral vectors were produced using
a phR-SIN-SFFV-pLuc-IRES-GFP transfer vector57 after the deletion of GFP. This
vector was employed to quantify tumour growth in vivo without affecting the RGB
marking. In vivo bioluminescent quantification was performed using an IVIS
Lumina3 image system (Perkin Elmer). Mice were anesthetized with 2% isoflurane
and were imaged in ventral positions 1 min after the intravenous administration of
100 µl of a D-luciferin solution (12.5 mg/ml in PBS). Data were analysed using
Living Image software (Perkin Elmer). Quantification was performed by sub-
tracting mouse background average radiance from the ROI average radiance of
primary tumours and thorax. For subcutaneous in vivo growth kinetic studies,
normalization was calculated as fold change to day 1 after implantation or by the
basal cell line luminescence (SCLL) measured in vitro. SCLL was calculated as
luciferase activity per µg of protein. For orthotopic studies, the normalization factor
is represented by the average radiance 4 h post inoculation. For animal experi-
mentation, researchers were not blind; researchers involved in flow cytometry data
acquisition and LAM-PCR analysis were blind.
SKY analysis. RAINBONE cells and explanted tumour cells underwent molecular
cytogenetic analysis. Cultured adherent cells were treated with colchicine (0.5 μg/ml)
for 4 h at 37 °C and routinely harvested. Metaphases were prepared using a con-
ventional cytogenetic protocol for methanol/acetic acid (3:1)-fixed cells. Slides were
prepared from the fixed material and hybridized using the SKY method according to
the manufacturer’s protocol (Applied Spectral Imaging). Images were acquired with
an SD300 Spectra Cube (Applied Spectral Imaging) mounted on a Axioplan micro-
scope (Zeiss) using a custom-designed optical filter, SKY-1 (Chroma Technology). Up
to 15 metaphase cells were captured and analysed for each cell line when possible.
Genomic insertion site analysis by LAM-PCR. Lentiviral integration site analysis
was performed by a modified LAM-PCR58,59. This method amplifies the DNA
around the viral/host junction and identifies the adjacent host DNA by sequencing.
A single-stranded copy of the proviral-host junction was made by linear extension
from a biotinylated viral LTR primer; this single-stranded junction fragment was
trapped and isolated on streptavidin-coated magnetic beads, and a second strand
was generated by random-primed polymerization. The host sequence was cut at the
nearest RsaI or HeaIII restriction site and ligated to an anchor primer; the junction
region was amplified by nested PCR. The complexity of the population of inte-
gration sites was initially monitored by running PCR products on 4–20% poly-
acrylamide gel. Individual insertion sites were identified by cloning and sequencing
individual bands. The non-viral sequence from each band was used to search the
mouse genome using a BLAST search on the University of California Santa Cruz
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Genome Browser. Uncropped polyacrylamide gels images are presented in Sup-
plementary Figure 12.
Statistical analysis. Data were graphed with GraphPad Prism (GraphPad Soft-
ware) and Excel service pack (Microsoft software). Statistical analyses were
performed by GraphPad Prism (GraphPad Software). Data are expressed as the
means ± SD unless otherwise specified. In boxplots graphs, centre line indicates
median, bounds of box indicate 25th and 75th percentiles, and whiskers indicate
minimum and maximum. Correlation between two parameters was estimated by
Pearson's coefficient of correlation, by two-tailed tests, and with a confidence
interval of 95%. P values less than 0.05 were considered statistically significant.
One-way or two-way analysis of variance (ANOVA) with Bonferroni post-testing
was used to compare significant differences for more than two groups. For multiple
comparisons, a confidence interval of 95% was adopted, and only P values lower
than 0.05 were considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001,
and ****P < 0.0001 were deemed statistically significant.
Data availability
Datasets generated and analysed in the study are available from the corresponding author
upon reasonable request.
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